COMMUNIQUÉS West-GlobeNewswire

-
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
06/05/2024 -
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
06/05/2024 -
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
06/05/2024 -
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
06/05/2024 -
ImPact Biotech Presents Preliminary Phase 3 Results from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
06/05/2024 -
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
06/05/2024 -
Vor Bio to Participate in Upcoming Investor Conferences
06/05/2024 -
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
06/05/2024 -
aTyr Pharma to Present at Upcoming Investor Conferences
06/05/2024 -
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
06/05/2024 -
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
06/05/2024 -
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
06/05/2024 -
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
06/05/2024 -
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
06/05/2024 -
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
06/05/2024 -
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
06/05/2024 -
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
06/05/2024 -
A Message to Our Valued Stakeholders - We're Here for the Long Haul
06/05/2024 -
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
06/05/2024
Pages